ClinicalTrials.gg
CompletedNCT07355738Updated Nov 10, 2026

Bioequivalence Study of GZR18 Injection Before and After CMC Change

A Phase 1 interventional study of GZR18 injection A and GZR18 injection B in Obesity&T2D, sponsored by Gan & Lee Pharmaceuticals.. Completed at 1 site in China. Open to male participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Gan & Lee Pharmaceuticals. · Phase 1, Interventional, and Other

Updated Nov 10, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
266
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing bofanglutide in Obesity — 3 open to participants now, 3 under way, 3 of them phase 3. bofanglutide · Obesity.

Enrollment
6th of 15
266 · median 140
Started
2026
with 3 others
Phase 1
7 of 15
none open now
Registered
13th of 15
by date
Lead sponsor
9 of 15
Gan & Lee Pharmaceuticals.

Among the 15 studies testing bofanglutide in Obesity, this one is the 6th largest by enrollment, is one of 4 that started in 2026, is one of 7 in phase 1, and was the 13th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

3 of the 15 studies testing bofanglutide in Obesity are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

About bofanglutide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 50 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing bofanglutide in Obesity, or all of them as a file.
02

Study summary

This is an open-label, randomized, single-dose, parallel comparison bioequivalence study conducted in healthy adult male subjects.

The study is divided into 3 parts, each of which evaluates the bioequivalence of GZR18 Injection for one strength before and after CMC changes.

Subjects eligible for each part of the screening will be randomized into Group A or Group B in a 1:1 ratio. Each subject will receive a single dose of GZR18 Injection, followed by PK blood sampling and safety follow-up for 35 days. Subjects will be admitted to the hospital 1 day predose, follow a standardized light diet that evening, and then fast for at least 10 h thereafter. On the day of administration, GZR18 Injection of a single strength will be administered subcutaneously under fasting conditions at a site approximately two finger-widths (2.5 cm) away from the umbilicus on the abdomen. Lunch and dinner will be served approximately 3 and 9 h postdose, respectively.

Venous blood will be collected at 14 time points for GZR18 plasma concentration analysis: at 0 h (within 60 min predose) and 1, 6, 24, 48, 72, 96, 120, 168, 240, 336, 504, 672, and 840 h postdose.

Subjects will undergo corresponding laboratory safety tests at screening, D36, and early withdrawal visits.

During the entire study period, subjects should maintain a light diet, avoid strenuous exercise, and refrain from consuming juice, caffeinated beverages (such as tea and coffee), and alcoholic drinks. Smoking and any other activities that may affect PK observation or safety evaluations are strictly prohibited.

03

Conditions studied

  • Obesity&T2D

Browse trials for

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects who voluntarily sign the Form (ICF), can receive SC injection, fully understand the content, process and possible adverse reactions of the trial, and are able to follow the regulations on and restrictions specified in this protocol.
  2. Male, 18 to 50 years of age at signing the ICF (both inclusive).
  3. Weight ≥ 50 kg and (BMI) within 19-26 kg/m2 (inclusive) at screening.
  4. Subjects of with no birth plan from the signing of ICF to 8 weeks after the last dose, willingness to take effective measures, and no plan for sperm donation.

    -

Exclusion criteria

Exclusion Criteria:

  1. Subjects with abnormalities detected during the screening period in physical examination, vital signs, laboratory tests, 12-lead , abdominal ultrasound, or chest X-ray, as determined by the investigator.
  2. Subjects who test positive for virus surface antigen, virus IgG antibody, antibody, P24 antigen, or anti-treponema pallidum antibody.
  3. Subjects with a history of or existing circulatory, urinary, digestive, respiratory, nervous, endocrine, or psychiatric disorders that, in the investigator's judgment, remain clinically significant.
  4. History of acute or chronic pancreatitis and pancreatic injury before screening.
  5. History or family history of previous or existing medullary thyroid carcinoma, multiple endocrine neoplasia type 2.
  6. Subjects who have used any drugs that alter the activity of drug metabolizing enzymes or transporters within 4 weeks prior to screening, or subjects with acute diseases or concomitant medication from the screening period to before randomization.
  7. Subjects with severe infection or unexplained infection within 4 weeks before screening.
  8. Major surgery within 6 months prior to screening, or scheduled surgery or hospitalization during the study.
  9. Subjects known or suspected to have to any ingredient of the medicinal product (IMP) (glucagon like peptide-1 receptor agonist (GLP-1RA) or its ).
  10. Use of any prescription drugs, over-the-counter drugs or Chinese herbal medicine within 2 weeks prior to screening; use of any GLP-1R agonists or drugs with the same mechanism of action to GLP-1R agonists (such as GLP-1R/glucagon receptor [GCGR] agonists or gastric inhibitory polypeptide receptor [GIPR]/GLP-1R agonists or GIPR/GLP-1R/GCGR agonists) within 3 months prior to screening.
  11. Subjects who have been vaccinated within 1 month before screening or are scheduled for vaccination during the study.
  12. Blood donation or blood loss greater than or equal to 400 mL within 3 months before screening, or blood donation scheduled during the study or within 8 weeks after the end of the study.
  13. History of drug abuse prior to screening; or positive results for drug abuse at screening (D-1).
  14. History of alcohol abuse within 3 months prior to screening, defined as an average intake of more than 14 units per week (1 standard unit=360 mL of beer or 150 mL of 12% wine or 45 mL of 40% spirits); or use of any alcohol-containing products 48 hours before administration; or abnormal results for breath alcohol test at screening (D-1).
  15. Subjects who smoked more than 5 cigarettes per day on average within the 3 months before screening, or who do not agree to abstain from smoking for the duration of the study.
  16. Subjects who engage in strenuous exercise within 48 h before administration of the IMP, or have other factors that may affect drug absorption, distribution, metabolism, or excretion.
  17. Subjects who consume grapefruit or grapefruit-containing products, or any caffeinated or xanthine-containing foods or beverages (such as coffee, tea, cola, or chocolate) within 48 hours before administration of the IMP.
  18. Subjects who have special dietary requirements and cannot adhere to a standardized diet, or who are lactose intolerant.
  19. Subjects with a history of needle phobia and blood phobia, difficulty in blood collection or intolerance to venous blood collection.
  20. Subjects who are investigators or employees of the study site, or family members of the employees or investigators.
  21. Participation in a clinical study of another IMP or device within 3 months before screening, or within 5 half-lives of the previous IMP (whichever is longer). Or plan to participate in another clinical study of an IMP or device before completing all scheduled assessments in the clinical study.

    -

Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
266 participants (actual)

Study arms

  • Experimental
    GZR18 injection A1

    Single dose, s.c.

    Drug: GZR18 injection A

  • Experimental
    GZR18 injection B1

    Single dose, s.c.

    Drug: GZR18 injection B

  • Experimental
    GZR18 injection A2

    Drug: GZR18 injection A

  • Experimental
    GZR18 injection B2

    Drug: GZR18 injection B

  • Experimental
    GZR18 injection A3

    Drug: GZR18 injection A

  • Experimental
    GZR18 injection B3

    Drug: GZR18 injection B

Interventions

06

What researchers measure

Primary outcomes

  1. the maximum concentration (Cmax)

    Time frame: Day1-Day36

  2. the area under the concentration-time curve during a dosing interval (AUC0-t)

    Time frame: Day1-Day36

  3. the area under the concentration-time curve from the time of dosing extrapolated to infinity (AUC0-∞)

    Time frame: Day1-Day36

Secondary outcomes

  1. AUC extrapolated from the last time point extrapolated to infinity in percentage of the AUC0-∞ (AUC_%Extra)

    Time frame: Day1-Day36

  2. time of maximum observed concentration (Tmax)

    Time frame: Day1-Day36

  3. elimination half-life (t1/2)

    Time frame: Day1-Day36

  4. elimination rate constant of plasma concentration at terminal phase (λz)

    Time frame: Day1-Day36

  5. Treatment-Emergent Adverse Events (TEAEs)

    Time frame: Day1-Day36

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2026 to primary completion in May 2026, 4 months.

Of 335 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 4 months is below that.

Counting every sponsor, half of 440 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2026
First posted
Jan 21, 2026
StartActual
Jan 9, 2026
Primary completionActual
May 22, 2026
CompletionActual
May 22, 2026
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 10, 2026
Primary completion
May 20, 2026→May 22, 2026 (actual)
Nov 10, 2026
Study completion
May 20, 2026→May 22, 2026 (actual)
Nov 10, 2026
Enrollment
138 (estimated)→266 (actual)
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Recruiting→Completed
    Primary completion May 20, 2026→May 22, 2026 (now actual)
    Study completion May 20, 2026→May 22, 2026 (now actual)
    Enrollment 138 (estimated)→266 (actual)
    + 2 other changes: contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07355738
Responsible party
Sponsor
First posted
Jan 21, 2026
Start date
Jan 9, 2026
Primary completion
May 22, 2026
Completion
May 22, 2026
Last update
Nov 10, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bofanglutide

Start the discussion